Sign Out
Recommended Dose: Adults and children over 12 years: Recommended therapy is one drop of OPTIMOLOL in the affected eye(s) twice a day.
OPTIMOLOL is available in 0.5% strength. It is not able to deliver other recommended dose of Timolol.
Source alternative product for other recommended dosage.
Elderly: Dosage need not be modified for the elderly as there has been wide experience with the use of OPTIMOLOL in elderly patients. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity. Intraocular pressure should be reassessed approximately four weeks after starting treatment because response to OPTIMOLOL may take a few weeks to stabilise. Provided that intraocular pressure is maintained at satisfactory levels, many patients can then be placed on once daily therapy. If necessary, concomitant treatment with miotics, epinephrine and/or carbonic anhydrase inhibitors can be instituted. In order to prevent the active substance(s) from being washed out when additional ophthalmic medication is used, an interval of at least 10 minutes between each application is recommended.
The use of two topical beta-adrenergic agents is not recommended.
Transfer from other topical beta-blocking agents: Discontinue use after a full day of therapy and start treatment with OPTIMOLOL the next day, with one drop in each affected eye twice daily.
Transfer from a single antiglaucoma agent other than a topical beta-blocking agent: Continue the agent and add one drop of OPTIMOLOL in each affected eye twice daily. On the following day, discontinue the previous agent completely, and continue with OPTIMOLOL. Patients should be instructed to remove soft contact lenses before using timolol.
Paediatric Population: Due to limited data, Timolol could only be recommended for use in Primary congenital and primary juvenile glaucoma for a transitional period while decision is made on a surgical approach and in case of failed surgery while awaiting further options.
Posology: Clinicians should strongly evaluate the risks and benefits when considering medical therapy with Timolol in paediatric patients. A detailed paediatric history and examination to determine the presence of systemic abnormalities should precede the use of Timolol. No specific dosage recommendation can be given as there is only limited clinical data. However, if benefit outweighs the risk, it is recommended to use the lowest active agent concentration available once daily. If IOP could not be sufficiently controlled, a careful up titration to a maximum of two drops daily per affected eye has to be considered. If applied twice daily, an interval of 12 hours should be preferred. Furthermore, the patients, especially neonates, should be strongly observed after the first dose for one to two hours in the office and closely monitored for ocular and systemic side effects until surgery is performed. With regard to pediatric use, the 0.1 % active agent concentration might already be sufficient.
Method of administration: To limit potential adverse effects only one drop should be instilled per dosing time. Systemic absorption of topically administered beta-blockers can be reduced by nasolacrimal occlusion and by keeping the eyes closed as long as possible after instillation of drops.
Duration of treatment: For a transient treatment in the paediatric population.
Usage Instruction: 1. Ensure that hands are clean.
2. To open the bottle, unscrew the cap of the bottle.
3. Check the tip to make sure it is not cracked or chipped.
4. Tilt the head back and pull lower eyelid down with a finger to form a pocket.
5. Invert the container, press lightly until a single drop is dispensed into the eye as directed by a doctor.
DO NOT TOUCH THE EYE OR EYELID WITH THE DROPPER TIP.
6. Repeat steps 4 and 5 with the other eye if instructed to do so by the doctor.
7. Replace the cap by turning until it is firmly touching the bottle.
Route of Administration: For Ophthalmic Use Only.
